Genome Alert!: A standardized procedure for genomic variant reinterpretation and automated gene-phenotype reassessment in clinical routine.


Journal

Genetics in medicine : official journal of the American College of Medical Genetics
ISSN: 1530-0366
Titre abrégé: Genet Med
Pays: United States
ID NLM: 9815831

Informations de publication

Date de publication:
06 2022
Historique:
received: 30 11 2021
revised: 07 02 2022
accepted: 07 02 2022
pubmed: 22 3 2022
medline: 3 6 2022
entrez: 21 3 2022
Statut: ppublish

Résumé

Retrospective interpretation of sequenced data in light of the current literature is a major concern of the field. Such reinterpretation is manual and both human resources and variable operating procedures are the main bottlenecks. Genome Alert! method automatically reports changes with potential clinical significance in variant classification between releases of the ClinVar database. Using ClinVar submissions across time, this method assigns validity category to gene-disease associations. Between July 2017 and December 2019, the retrospective analysis of ClinVar submissions revealed a monthly median of 1247 changes in variant classification with potential clinical significance and 23 new gene-disease associations. Re-examination of 4929 targeted sequencing files highlighted 45 changes in variant classification, and of these classifications, 89% were expert validated, leading to 4 additional diagnoses. Genome Alert! gene-disease association catalog provided 75 high-confidence associations not available in the OMIM morbid list; of which, 20% became available in OMIM morbid list For more than 356 negative exome sequencing data that were reannotated for variants in these 75 genes, this elective approach led to a new diagnosis. Genome Alert! (https://genomealert.univ-grenoble-alpes.fr/) enables systematic and reproducible reinterpretation of acquired sequencing data in a clinical routine with limited human resource effect.

Identifiants

pubmed: 35311657
pii: S1098-3600(22)00654-2
doi: 10.1016/j.gim.2022.02.008
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1316-1327

Informations de copyright

Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict of Interest K.Y., M.B., R.L., Q.F., A.D., N.S., D.B., A.-L.B., and N.D.-F. are partially or fully employed by SeqOne Genomics; J.M-H., S.B, J.A., and N.P. hold shares in SeqOne Genomics; D.T., A.B., A.L., and J.-M.C. are partially or fully employed by Laboratoire Cerba. V.G. and L.R. are partially or fully employed by Laboratoire Eurofins Biomnis. All other authors declare no conflicts of interest.

Auteurs

Kevin Yauy (K)

Institute for Advanced Biosciences, Centre de recherche UGA / Inserm U 1209 / CNRS UMR 5309, Grenoble, France; SeqOne Genomics, Montpellier, France. Electronic address: kevin.yauy@univ-grenoble-alpes.fr.

François Lecoquierre (F)

Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Rouen, France.

Stéphanie Baert-Desurmont (S)

Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Rouen, France.

Detlef Trost (D)

Laboratoire Cerba, Saint-Ouen-l'Aumône, France.

Aicha Boughalem (A)

Laboratoire Cerba, Saint-Ouen-l'Aumône, France.

Armelle Luscan (A)

Laboratoire Cerba, Saint-Ouen-l'Aumône, France.

Jean-Marc Costa (JM)

Laboratoire Cerba, Saint-Ouen-l'Aumône, France.

Vanna Geromel (V)

Laboratoire Eurofins Biomnis, Lyon, France.

Laure Raymond (L)

Laboratoire Eurofins Biomnis, Lyon, France.

Pascale Richard (P)

Unité Fonctionnelle de Cardiogénétique et Myogénétique, Centre de Génétique, Hôpitaux Universitaire Pitié Salpêtrière-Charles Foix, Paris, France.

Sophie Coutant (S)

Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Rouen, France.

Mélanie Broutin (M)

SeqOne Genomics, Montpellier, France.

Raphael Lanos (R)

SeqOne Genomics, Montpellier, France.

Quentin Fort (Q)

SeqOne Genomics, Montpellier, France.

Stenzel Cackowski (S)

Grenoble Institut Neurosciences, GIN, Inserm U1216, Université de Grenoble Alpes, Grenoble, France.

Quentin Testard (Q)

Institute for Advanced Biosciences, Centre de recherche UGA / Inserm U 1209 / CNRS UMR 5309, Grenoble, France; Laboratoire Eurofins Biomnis, Lyon, France.

Abdoulaye Diallo (A)

SeqOne Genomics, Montpellier, France.

Nicolas Soirat (N)

SeqOne Genomics, Montpellier, France.

Jean-Marc Holder (JM)

SeqOne Genomics, Montpellier, France.

Nicolas Duforet-Frebourg (N)

SeqOne Genomics, Montpellier, France.

Anne-Laure Bouge (AL)

SeqOne Genomics, Montpellier, France.

Sacha Beaumeunier (S)

SeqOne Genomics, Montpellier, France.

Denis Bertrand (D)

SeqOne Genomics, Montpellier, France.

Jerome Audoux (J)

SeqOne Genomics, Montpellier, France.

David Genevieve (D)

Medical Genetic Department for Rare Diseases and Personalized Medicine, Montpellier University Hospital, Montpellier, France.

Laurent Mesnard (L)

Soins Intensifs Néphrologiques et Rein Aigu, Hôpital Tenon, Assistance Publique des Hôpitaux de Paris, Paris, France; UMR_S1155, INSERM, Sorbonne Université, Paris, France.

Gael Nicolas (G)

Department of Genetics and Reference Center for Developmental Disorders, Normandy Center for Genomic and Personalized Medicine, Normandie Univ, UNIROUEN, Inserm U1245 and Rouen University Hospital, F 76000, Rouen, France.

Julien Thevenon (J)

Institute for Advanced Biosciences, Centre de recherche UGA / Inserm U 1209 / CNRS UMR 5309, Grenoble, France.

Nicolas Philippe (N)

SeqOne Genomics, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH